Radiation therapy by infusion
Radium-223 (Xofigo): Castration-resistant prostate cancer that has spread to the bone can be treated with this radioactive substance. Alpha-emitting radionuclide radium-223 targets the areas of the bone where cancer is causing changes and mimics calcium. This therapy conveys radiation particles straightforwardly to growths tracked down in the bone, restricting harm to solid tissue, including the bone marrow, where ordinary platelets are made. For six months, radium-223 is administered intravenously (IV) once per month. A radiation oncologist or a nuclear medicine physician will administer this treatment. Throughout this treatment, your medical oncologist should continue to monitor your progress to ensure that the treatment is effective and that any potential side effects are managed. Radium-233 treatment does not always lower PSA, so patients should not anticipate significant PSA levels dropping during treatment; in fact, PSA levels may frequently rise.
This treatment should not be given to some people, especially those with prostate cancer that has spread to the liver, lungs, or both, or with lymph nodes that are three centimeters or larger in diameter. Radium-223 ought not be utilized in mix with abiraterone and prednisone since that blend builds the gamble of bone cracks. Check with your doctor to see if you might benefit from taking this medication.
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto): This treatment, also known as 177Lu-PSMA-617, delivers radiation directly to the cancer cells by targeting a specific protein known as PSMA (prostate-specific membrane antigen), which is highly expressed on prostate cancer cells. It is approved for the treatment of metastatic castration-resistant prostate cancer patients who have previously received docetaxel and an AR inhibitor. A specific kind of positron-emission tomography (PET) scan must demonstrate that the cancer cells express PSMA before this treatment can be administered (see Diagnosis). Fatigue, dry mouth, nausea, anemia, a loss of appetite, constipation, and anemia are the most common adverse effects of this treatment.
Dr. Amit Ghosh is one of the best urologist and robotics uro-surgeon in Kolkata. After his return from the UK, he has been associated with various institutions including Wockhardt Hospital and Kidney Institute, Woodlands Hospital, Kothari Medical Center and Anandalok Hospital. Currently he is dedicated to his service to Apollo Gleneagles Hospitals, Kolkata. Currently he has developed a very well established and robust Urological presence in the campus of Apollo Gleneagles Hospitals, Kolkata. The practice takes care of all fundamental general Urological procedures, a vast multi-disciplinary Uro Oncology specialty, and also a comprehensive diagnostic and uro health check-up facility.


Comments
Post a Comment